AI assistant
HAEMONETICS CORP — Director's Dealing 2019
May 16, 2019
31565_dirs_2019-05-16_b88f092e-0eb0-42da-b86c-b62e6fd5b508.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-05-14
Reporting Person: Bolorforosh Said (EVP, Chief Technology Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-14 | Common Stock | A | 1275 | — | Acquired | 2210 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-14 | Non-qualified Stock Option (Right to Buy) | $98.025 | A | 4451 | Acquired | 2026-05-14 | Common Stock (4451) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.